SK Biopharmaceuticals Co., Ltd. (326030.KS) reported that its third quarter net income attributable to shareholders of parent company climbed to 74.14 billion won from 9.66 billion won last year.
Quarterly operating income was 70.11 billion won, up from 19.34 billion won in the same quarter last year.
Sales for the quarter grew to 191.73 billion won from 136.60 billion won in the prior year.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.